While the basic principles of personalized medicine and pharmacogenomics has been covered by numerous texts, there are none to date that focuses on the specific tests themselves that are in current clinical practice and those that are being proposed for implementation in the near future. Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory focuses almost entirely on the specifics of each test that is needed to implement these tests into a clinical laboratory. This volume presents the first compilation of the tests currently in routine clinical use.…mehr
While the basic principles of personalized medicine and pharmacogenomics has been covered by numerous texts, there are none to date that focuses on the specific tests themselves that are in current clinical practice and those that are being proposed for implementation in the near future. Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory focuses almost entirely on the specifics of each test that is needed to implement these tests into a clinical laboratory. This volume presents the first compilation of the tests currently in routine clinical use. The chapter authors of this unique and invaluable title comprise a range of renowned authorities and investigators who have conducted the essential clinical trials necessary to justify pharmacogenomic testing today. The book is divided into four parts: Basic Concepts, Specific Pharmacogenomic Targets, Drugs that Cause Delayed Hypersensitivity, and Miscellaneous Drugs. Each author provides a pharmacologic background on the target drug, the need for pharmacogenomic testing, and how results can be translated into clinical decisions. Where appropriate, case studies are given to illustrate typical clinical scenarios. An extensive bibliography is provided so that the reader can refer to the original studies. This well-designed resource will appeal to clinical laboratory directors who are contemplating or assigned the task of establishing a pharmacogenomics laboratory and a wide range of clinicians who must interpret results of testing. Focused and immensely useful, Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory is a timely and outstanding contribution to the literature and will be instrumental in defining this rapidly growing field.
Die Herstellerinformationen sind derzeit nicht verfügbar.
Inhaltsangabe
Part 1. Basic concepts
Chapter 1. Issues in Translation of Pharmacogenomics into Clinical Practice.
Kiang-Teck J. Yeo, Nikolina Babic, Alan H.B. Wu
Chapter 2. Molecular Diagnostic Methods in Pharmacogenomics
Nikolina Babic*, Loren J. Joseph, Kiang-Teck J. Yeo
Chapter 3. Economics of pharmacogenomic testing in clinical practice
Alan H.B. Wu
Chapter 4. From Personalized Medicine to Personalized Justice: The Promises of Translational Pharmacogenomics in the Justice System
Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.
Part 2. Specific pharmacogenomic targets: Chemotherapeutics
Chapter 5. Irinotecan
R. Stephanie Huang, Federico Innocenti and Mark J. Ratain
Chapter 6. Pharmacogenomics of tamoxifen
Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman
Chapter 7. Thiopurines
Terreia S. Jones, Mary V. Relling
Part 3. Specific pharmacogenomic targets: Cardiovascular drugs
Chapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs
Charles Eby
Chapter 9. Clopidogrel and Salicylates
Janice Y Chyou, Marc S Sabatine
Chapter 10. DNA-Guided Statin Therapy
Gualberto Ruaño, Richard L. Seip, Jorge Duconge
Chapter 11. The statin response gene: Kif6
....................... H. Robert Superko, Tom White, James Forrester, Spencer King III.
Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Hong-Kee Lee, Lionel D. Lewis
Chapter 16. Immunosuppressants Pharmacogenomics
Ping Wang
Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.
Part 2. Specific pharmacogenomic targets: Chemotherapeutics
Chapter 5. Irinotecan
R. Stephanie Huang, Federico Innocenti and Mark J. Ratain
Chapter 6. Pharmacogenomics of tamoxifen
Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman
Chapter 7. Thiopurines
Terreia S. Jones, Mary V. Relling
Part 3. Specific pharmacogenomic targets: Cardiovascular drugs
Chapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs
Charles Eby
Chapter 9. Clopidogrel and Salicylates
Janice Y Chyou, Marc S Sabatine
Chapter 10. DNA-Guided Statin Therapy
Gualberto Ruaño, Richard L. Seip, Jorge Duconge
Chapter 11. The statin response gene: Kif6
....................... H. Robert Superko, Tom White, James Forrester, Spencer King III.
Chapter 1. Issues in Translation of Pharmacogenomics into Clinical Practice.
Kiang-Teck J. Yeo, Nikolina Babic, Alan H.B. Wu
Chapter 2. Molecular Diagnostic Methods in Pharmacogenomics
Nikolina Babic*, Loren J. Joseph, Kiang-Teck J. Yeo
Chapter 3. Economics of pharmacogenomic testing in clinical practice
Alan H.B. Wu
Chapter 4. From Personalized Medicine to Personalized Justice: The Promises of Translational Pharmacogenomics in the Justice System
Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.
Part 2. Specific pharmacogenomic targets: Chemotherapeutics
Chapter 5. Irinotecan
R. Stephanie Huang, Federico Innocenti and Mark J. Ratain
Chapter 6. Pharmacogenomics of tamoxifen
Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman
Chapter 7. Thiopurines
Terreia S. Jones, Mary V. Relling
Part 3. Specific pharmacogenomic targets: Cardiovascular drugs
Chapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs
Charles Eby
Chapter 9. Clopidogrel and Salicylates
Janice Y Chyou, Marc S Sabatine
Chapter 10. DNA-Guided Statin Therapy
Gualberto Ruaño, Richard L. Seip, Jorge Duconge
Chapter 11. The statin response gene: Kif6
....................... H. Robert Superko, Tom White, James Forrester, Spencer King III.
Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Hong-Kee Lee, Lionel D. Lewis
Chapter 16. Immunosuppressants Pharmacogenomics
Ping Wang
Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.
Part 2. Specific pharmacogenomic targets: Chemotherapeutics
Chapter 5. Irinotecan
R. Stephanie Huang, Federico Innocenti and Mark J. Ratain
Chapter 6. Pharmacogenomics of tamoxifen
Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman
Chapter 7. Thiopurines
Terreia S. Jones, Mary V. Relling
Part 3. Specific pharmacogenomic targets: Cardiovascular drugs
Chapter 8. The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs
Charles Eby
Chapter 9. Clopidogrel and Salicylates
Janice Y Chyou, Marc S Sabatine
Chapter 10. DNA-Guided Statin Therapy
Gualberto Ruaño, Richard L. Seip, Jorge Duconge
Chapter 11. The statin response gene: Kif6
....................... H. Robert Superko, Tom White, James Forrester, Spencer King III.
Chapter 15. Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury
Hong-Kee Lee, Lionel D. Lewis
Chapter 16. Immunosuppressants Pharmacogenomics
Ping Wang
Rezensionen
From the reviews: "The book is written for clinical laboratory directors 'contemplating or assigned the task of establishing a pharmacogenomics laboratory,' pharmacologists, and interested clinicians who may have to interpret results. This book also would be of interest to ... allied health practitioners, regulators, reimbursers, and test device manufacturers. ... The writing is concise, clear, and accessible for what might be considered a complex topic. ... Get this book if you want a quick, concise, and fascinating read about the current world and use of pharmacogenomic testing." (Valerie L. Ng, Doody's Review Service, May, 2011)
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826